ClinicalTrials.gg
RecruitingNCT07644559Updated Nov 13, 2026

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

A Phase 2 interventional study of VS-7375 and cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) in Pancreatic Ductal Adenocarcinoma (PDAC) and G12D Mutated KRAS, sponsored by Verastem, Inc.. Recruiting at 38 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Verastem, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 23, 2026First site in Puerto RicoEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 299 open to participants now, 472 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
190th of 1,574
185 · median 37
Started
2026
with 83 others
Phase 2
488 of 1,851
45 open now
Primary completion
2027-06
later than 214 of 471 live
Registered
1,813th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 190th largest by planned enrollment of the 1,574 interventional ones that give a count, is one of 84 that started in 2026, is one of 488 in phase 2, reaches primary completion later than 214 of the 471 other live ones, and was the 1,813th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

299 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

294 more — sign in →

All 299 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • G12D Mutated KRAS

Keywords

  • KRAS G12D mutation
  • KRAS
  • PDAC
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
  • Pancreatic Neoplasms
  • RAS
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic or cytologic confirmed PDAC
  • per 1.1
  • Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • PS=0 or 1

Adequate organ function

VS-7375 + cetuximab (2L PDAC) :

-Received only 1 prior Tx in the setting; prior adjuvant counts as a line if progressed within 6 months

VS-7375 + cetuximab (1L PDAC) :

-Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease

Exclusion criteria

Exclusion criteria:

  • Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s) in KRAS
  • Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • Major surgery within 4 weeks of first treatment dose
  • Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose
  • History of drug-induced Interstitial Lung Disease
  • Receipt of prior direct RAS inhibitor
  • Untreated or symptomatic
  • Receipt of strong inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
  • Receipt of PPI, P-CABs, or H2 blocker within 5 days
  • Inability to swallow oral medication
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    VS-7375 Monotherapy

    Drug: VS-7375

  • Experimental
    VS-7375 + cetuximab 2L PDAC

    Drug: VS-7375 · Drug: cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)

  • Experimental
    VS-7375 + cetuximab 1L PDAC

    Drug: VS-7375 · Drug: cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)

Interventions

  • Taken by mouth

  • Drugcetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)

    Drug page: Cetuximab

    Subcutaneous infusion

06

What researchers measure

Primary outcomes

  1. Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1

    Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)

    Time frame: 6 months

  2. To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.

    Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations.

    Time frame: 6 months

Secondary outcomes

  1. Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments.

    To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.

    Time frame: 24 months

  2. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax

    Maximum concentration (Cmax)

    Time frame: 20 weeks

  3. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC

    Area under plasma Concentration (AUC) 0 to t

    Time frame: 20 weeks

  4. To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type

    CA19-9, CEA, CA-125

    Time frame: Up to 2.5 years

  5. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30).

    The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of pancreatic ductal adenocarcinoma patients.

    Time frame: 24 months

  6. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module QLQ-PAN26.

    The EORTC QLQ-PAN26 assesses the health-related QoL in patients with pancreatic cancer. QLQ-PAN26 includes 26 items related to disease symptoms, treatment side-effects, and emotional issues specific to pancreatic cancer.

    Time frame: 24 months

  7. Time to next therapy.

    To assess the interval between initiation of study treatment and initiation of subsequent

    Time frame: 24 months

Other outcomes

  1. Imaging of tumor metabolism changes

    To assess tumor metabolism dynamics on FDG-PET/CT

    Time frame: 24 months

07

Study locations

38 of 38 sites recruiting
08

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 12, 2026
StartActual
Jun 16, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added — first site in Puerto Rico
Show 9 added (4 Australia, 3 United States, 2 Puerto Rico)
  • University of Chicago · Chicago, United States
  • Calvary Mater Newcastle · Waratah, Australia
  • ICON Cancer Centre Townsville · Hyde Park, Australia
  • BRCR Global- San Juan · San Juan, Puerto Rico
  • BRCR- Yauco · Yauco, Puerto Rico
  • BRCR Global- Coral Springs · Coral Springs, United States
  • BRCR Global- Tamarac · Tamarac, United States
  • ICON Cancer Centre- Hobart · Hobart, Australia
  • Alfred Hospital · Melbourne, Australia
across 4 updates, Oct 9, 2026 – Oct 23, 2026
Enrollment
180→185
Oct 9, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHistopathologyHistologic or cytologic confirmed PDAC
Exclusion criteria
  • EditedHave any other documented co-existing commonpathogenic or likely pathogenic RAS mutation(s) in KRAS
  • EditedReceipt of PPI, P-CABs, or H2 blocker within 5 days
Oct 9, 2026
Interventions
Changed cetuximab→cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
Oct 9, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedTo assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30).Time frame: 24 months
  • AddedTo assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module QLQ-PAN26.Time frame: 24 months
Oct 9, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • University of Michigan · Ann Arbor, United StatesContact •••1125→•••1125
  • Sunnybrook Health Sciences Centre · Toronto, CanadaContact y•••@sunnybrook.ca · •••5000→c•••@sunnybrook.caContact removed r•••@sunnybrook.ca · •••5000
  • Calvary Mater Newcastle · Waratah, AustraliaContact R•••@health.nsw.gov.au · •••3282→K•••@health.nsw.gov.au
across 4 updates, Oct 9, 2026 – Nov 13, 2026
Show all 6 updates
  1. Nov 13, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Calvary Mater Newcastle · Waratah, AustraliaContact R•••@health.nsw.gov.au · •••3282→K•••@health.nsw.gov.au
  2. Nov 6, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sunnybrook Health Sciences Centre · Toronto, CanadaContact y•••@sunnybrook.ca · •••5000→c•••@sunnybrook.caContact removed r•••@sunnybrook.ca · •••5000
    + 1 other change: site details
  3. Oct 23, 2026
    1 site added
    Show site
    • Alfred Hospital · Melbourne, Australia
  4. Oct 19, 2026
    3 sites added
    Show 3 added (2 United States, 1 Australia)
    • BRCR Global- Coral Springs · Coral Springs, United States
    • BRCR Global- Tamarac · Tamarac, United States
    • ICON Cancer Centre- Hobart · Hobart, Australia
  5. Oct 13, 2026
    3 sites added — first site in Puerto Rico
    Show 3 added (2 Puerto Rico, 1 Australia)
    • ICON Cancer Centre Townsville · Hyde Park, Australia
    • BRCR Global- San Juan · San Juan, Puerto Rico
    • BRCR- Yauco · Yauco, Puerto Rico
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Michigan · Ann Arbor, United StatesContact •••1125→•••1125
  6. Oct 9, 2026
    2 sites added
    Show 2 added (1 United States, 1 Australia)
    • University of Chicago · Chicago, United States
    • Calvary Mater Newcastle · Waratah, Australia
    Enrollment 180→185
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHistopathologyHistologic or cytologic confirmed PDAC
    Exclusion criteria
    • EditedHave any other documented co-existing commonpathogenic or likely pathogenic RAS mutation(s) in KRAS
    • EditedReceipt of PPI, P-CABs, or H2 blocker within 5 days
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedTo assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30).Time frame: 24 months
    • AddedTo assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module QLQ-PAN26.Time frame: 24 months
    Interventions Changed cetuximab→cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Michigan · Ann Arbor, United StatesContact •••1125→•••1125
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07644559
Lead sponsor
Verastem, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 16, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Verastem Call Center
Contact
VS-7375-201TrialSupport@verastem.com
7812924204
Luke Chung, MD
Contact
VS-7375-201Medical@verastem.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor VS-7375

Start the discussion